Novo Nordisk Craters 16% — The End of the GLP-1 Monopoly?
This episode analyzes Novo Nordisk's recent 16% stock decline following CagriSema's clinical trial results. It explores the implications of intensifying competition with Eli Lilly's Zepbound and the broader economic impact of the company's shifting market performance.